Tumour lysis syndrome in myeloma

Netherlands Journal of Medicine

Volumn 60, Issue 6, 2002, Pages 263-

  Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; M PROTEIN; PREDNISONE; SYNDECAN; THALIDOMIDE; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; AUTOCRINE EFFECT; B LYMPHOCYTE; BONE MARROW CELL; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; LETTER; LYMPHOMA CELL; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; TUMOR CELL; TUMOR LYSIS SYNDROME; NOTE;

ANTINEOPLASTIC AGENTS, HORMONAL; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; TUMOR LYSIS SYNDROME;

EID: 2242432619     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Kerkhof JJ van de, Peters WG, Visser J, Creemers GJ. Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy. Neth J Med 2001;59(2):83-5.
2. Urashima M, Teoh G, Chauhan D, et al. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997;90(1):279-89.
3. Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematology 1999;105(4):938-41.